Scientists identify immune pathway that worsens tau-linked neurodegeneration

A team of researchers has traced an unexpected route by which the immune system may amplify brain damage in Alzheimer's disease and related conditions. The pathway begins not in the brain itself, but in the lymph nodes that drain fluid from it—and involves immune cells priming other immune cells to infiltrate and harm neurons.

The work, published in Nature Neuroscience, centers on a particular type of dendritic cell called cDC1. These cells are specialized sentries of the immune system, trained to capture foreign or damaged material and present it to other immune cells called CD8+ T cells, essentially saying: go find and destroy anything that looks like this. In mouse models engineered to develop tau-related neurodegeneration—the hallmark of Alzheimer's disease and some forms of frontotemporal dementia—researchers found that cDC1s were doing exactly that in the deep cervical lymph nodes, which sit at the base of the skull and filter fluid draining from the brain. They were priming CD8+ T cells to recognize brain antigens, sending them into the brain tissue where they accumulated and contributed to neuronal death.

When the researchers eliminated cDC1s in their mouse models, or blocked the specific mechanism by which these cells present antigens to T cells, the result was striking. CD8+ T cell infiltration into the brain dropped sharply—by roughly 50 percent. Brain tissue that would normally have atrophied in the piriform cortex, entorhinal cortex, and hippocampus was preserved. Male mice showed significantly lower levels of neurofilament light chain, a blood biomarker of neurodegeneration. The protective effect was not because cDC1 deficiency prevented tau from accumulating or becoming phosphorylated in the brain; rather, it appeared to short-circuit the immune system's attack on neurons already damaged by tau.

The researchers also injected T cells harvested from diseased mice into healthy mice with early tau pathology. Even without causing immediate neuronal death, these T cells triggered widespread glial activation—the inflammatory response of brain support cells—suggesting they prime the brain for further damage. The pathway, in other words, appears to be a feedback loop: tau damages neurons, neurons release antigens, dendritic cells capture those antigens and prime T cells, T cells infiltrate the brain and activate glia, which amplifies inflammation and accelerates neuronal loss.

When the team examined human tissue, the picture became more complicated. Postmortem brain samples from people with progressive supranuclear palsy, Pick's disease, and corticobasal degeneration—all primary tauopathies—showed markedly elevated CD8+ T cells in both gray and white matter compared to controls. A mouse model of frontotemporal dementia similarly showed increased brain T cells. But when researchers looked for evidence of cDC1 involvement in human cerebrospinal fluid and meningeal tissue, they found no clear differences between healthy people and those with Alzheimer's disease or mild cognitive impairment. The dendritic cell subsets and their antigen-presentation genes appeared stable across age groups and disease states.

This gap between the mouse findings and the human evidence is significant. The researchers have shown a causal mechanism in a controlled animal model—block cDC1s, reduce T cell infiltration, preserve brain tissue. They have shown that human tauopathy patients do have elevated brain CD8+ T cells. But they have not yet demonstrated that the same cDC1-dependent pathway is driving that infiltration in humans. The antigens that trigger the initial T cell response remain unknown, though immunological analysis has identified candidate peptides derived from tau itself, as well as from neurofilament light chain and other neuronal proteins.

The work opens a potential therapeutic avenue: if the cDC1-to-CD8+ T cell axis can be safely disrupted in humans, it might slow or prevent the immune-mediated damage that compounds tau pathology. But first, researchers must confirm that the pathway operates the same way in human brains, and identify which specific antigens are driving the T cell response. Until then, the findings remain a proof of concept—a hidden immune route that, in mice at least, makes neurodegeneration worse.